医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis

2019年04月25日 PM04:00
このエントリーをはてなブックマークに追加


 

BALLERUP, Denmark

LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005072/en/

The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies – which included 3,712 people with moderate-to-severe psoriasis – shows that 90% of patients treated with brodalumab who achieved PASI 100 also experienced sustained PASI 100. In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100. Study authors measured ‘sustained PASI 100’ as the time to inadequate response, based on a static physician’s global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period at or after week 16.1

Because the sub-populations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the study authors did not apply statistical comparisons.

Newer treatments for moderate-to-severe psoriasis have made it possible for patients to completely clear their skin, but the disease fluctuates over time, so we wanted to explore how fast and for how long patients can count on having complete skin clearance,” said Professor Lluís Puig, Director, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona. “These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab. That difference can have a big impact on patients’ quality of life.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005072/en/

CONTACT

LEO Pharma A/S
Trine Juul Wengel, Global External Communications
tewdk@leo-pharma.com
Tel.:
+45 72 60 86 18

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作